205 related articles for article (PubMed ID: 24365168)
1. Recurrence of morphea after successful ultraviolet A1 phototherapy: A cohort study.
Vasquez R; Jabbar A; Khan F; Buethe D; Ahn C; Jacobe H
J Am Acad Dermatol; 2014 Mar; 70(3):481-8. PubMed ID: 24365168
[TBL] [Abstract][Full Text] [Related]
2. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study.
Andres C; Kollmar A; Mempel M; Hein R; Ring J; Eberlein B
Br J Dermatol; 2010 Feb; 162(2):445-7. PubMed ID: 19785603
[TBL] [Abstract][Full Text] [Related]
3. Ultraviolet A1 phototherapy for the treatment of localized scleroderma.
Furuhashi T; Torii K; Ikumi K; Kato H; Nishida E; Morita A
J Dermatol; 2020 Jul; 47(7):792-795. PubMed ID: 32383187
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma.
Su O; Onsun N; Onay HK; Erdemoglu Y; Ozkaya DB; Cebeci F; Somay A
Int J Dermatol; 2011 Aug; 50(8):1006-13. PubMed ID: 21781079
[TBL] [Abstract][Full Text] [Related]
5. Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment.
Sator PG; Radakovic S; Schulmeister K; Hönigsmann H; Tanew A
J Am Acad Dermatol; 2009 May; 60(5):786-91. PubMed ID: 19211170
[TBL] [Abstract][Full Text] [Related]
6. Effects of UVA1 Phototherapy on Expression of Human Endogenous Retroviral Sequence (HERV)-K10 gag in Morphea: A Preliminary Study.
Kowalczyk MJ; Teresiak-Mikołajczak E; Dańczak-Pazdrowska A; Żaba R; Adamski Z; Osmola-Mańkowska A
Med Sci Monit; 2017 Jan; 23():505-512. PubMed ID: 28130554
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma.
Kreuter A; Hyun J; Stücker M; Sommer A; Altmeyer P; Gambichler T
J Am Acad Dermatol; 2006 Mar; 54(3):440-7. PubMed ID: 16488295
[TBL] [Abstract][Full Text] [Related]
8. Phototherapy with UVB narrowband, UVA/UVBnb, and UVA1 differentially impacts serum 25-hydroxyvitamin-D3.
Feldmeyer L; Shojaati G; Spanaus KS; Navarini A; Theler B; Donghi D; Urosevic-Maiwald M; Glatz M; Imhof L; Barysch MJ; Dummer R; Roos M; French LE; Surber C; Hofbauer GF
J Am Acad Dermatol; 2013 Oct; 69(4):530-6. PubMed ID: 23850091
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method.
de Rie MA; Enomoto DN; de Vries HJ; Bos JD
Dermatology; 2003; 207(3):298-301. PubMed ID: 14571073
[TBL] [Abstract][Full Text] [Related]
10. Ultraviolet A1 phototherapy beyond morphea: experience in 83 patients.
Connolly KL; Griffith JL; McEvoy M; Lim HW
Photodermatol Photoimmunol Photomed; 2015 Nov; 31(6):289-95. PubMed ID: 26052743
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea.
Kreuter A; Gambichler T; Avermaete A; Jansen T; Hoffmann M; Hoffmann K; Altmeyer P; von Kobyletzki G; Bacharach-Buhles M
Pediatr Dermatol; 2001; 18(3):241-5. PubMed ID: 11438008
[TBL] [Abstract][Full Text] [Related]
12. Biological effects of a new ultraviolet A
Arndt S; Lissner C; Unger P; Bäumler W; Berneburg M; Karrer S
Exp Dermatol; 2020 Dec; 29(12):1199-1208. PubMed ID: 32592187
[TBL] [Abstract][Full Text] [Related]
13. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma.
Kreuter A; Hyun J; Skrygan M; Sommer A; Tomi NS; Breuckmann F; Altmeyer P; Gambichler T
Arch Dermatol Res; 2006 Nov; 298(6):265-72. PubMed ID: 17009056
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of PUVA vs. UVA1 phototherapy in the treatment of morphea patients.
Malewska-Woźniak A; Osmola-Mañkowska A; Adamski Z
Postepy Dermatol Alergol; 2022 Aug; 39(4):757-761. PubMed ID: 36090739
[TBL] [Abstract][Full Text] [Related]
15. Low-dose UVA phototherapy for treatment of localized scleroderma.
Kerscher M; Volkenandt M; Gruss C; Reuther T; von Kobyletzki G; Freitag M; Dirschka T; Altmeyer P
J Am Acad Dermatol; 1998 Jan; 38(1):21-6. PubMed ID: 9448200
[TBL] [Abstract][Full Text] [Related]
16. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma.
Kreuter A; Hyun J; Skrygan M; Sommer A; Bastian A; Altmeyer P; Gambichler T
Br J Dermatol; 2006 Sep; 155(3):600-7. PubMed ID: 16911288
[TBL] [Abstract][Full Text] [Related]
17. UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-V.
Jacobe HT; Cayce R; Nguyen J
Br J Dermatol; 2008 Sep; 159(3):691-6. PubMed ID: 18544076
[TBL] [Abstract][Full Text] [Related]
18. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells.
Camacho NR; Sánchez JE; Martin RF; González JR; Sánchez JL
J Am Acad Dermatol; 2001 Nov; 45(5):697-9. PubMed ID: 11606918
[TBL] [Abstract][Full Text] [Related]
19. Ultraviolet A1 phototherapy: One center's experience.
Attili SK; Dawe RS; Ibbotson SH
Indian J Dermatol Venereol Leprol; 2017; 83(1):60-65. PubMed ID: 27212283
[TBL] [Abstract][Full Text] [Related]
20. Effects of low dose ultraviolet A-1 phototherapy on morphea.
Gruss CJ; Von Kobyletzki G; Behrens-Williams SC; Lininger J; Reuther T; Kerscher M; Altmeyer P
Photodermatol Photoimmunol Photomed; 2001 Aug; 17(4):149-55. PubMed ID: 11499534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
